Biowaiver for Capecitabine - FDA x EMA [Dissolution / BCS / IVIVC]

posted by Mauricio Sampaio  – Brazil, 2015-09-08 22:38 (3589 d 18:48 ago) – Posting: # 15390
Views: 14,014

Why FDA indicates a possibility to request a Biowaiver for Capecitabine (http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm083276.pdf) and EMA assumes that data on solubility does not allow the BCS classification of capecitabine (http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/07/WC500189272.pdf) ?

If both agencies are based on BCS classification from Amidon, who is correct? :confused:

Complete thread:

UA Flag
Activity
 Admin contact
23,428 posts in 4,929 threads, 1,680 registered users;
55 visitors (0 registered, 55 guests [including 23 identified bots]).
Forum time: 17:27 CEST (Europe/Vienna)

No matter what side of the argument you are on,
you always find people on your side
that you wish were on the other.    Thomas Berger

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5